[1] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 65: 87-108. 2015.
[2] R.L. Siegel, K.D. Miller, S.A. Fedewa, D.J. Ahnen, R.G. Meester, A. Barzi, A. Jemal. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017.
[3] R.J. Heald, E.M. Husband, R.D. Ryall. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? The British journal of surgery. 69: 613-616. 1982.
[4] R.J. Heald. The 'Holy Plane' of rectal surgery. Journal of the Royal Society of Medicine. 81: 503-508. 1988.
[5] W.E. Enker, H.T. Thaler, M.L. Cranor, T. Polyak. Total mesorectal excision in the operative treatment of carcinoma of the rectum. Journal of the American College of Surgeons. 181: 335-346. 1995.
[6] C. Rodel, P. Martus, T. Papadoupolos, L. Fuzesi, M. Klimpfinger, R. Fietkau, T. Liersch, W. Hohenberger, R. Raab, R. Sauer, C. Wittekind. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23: 8688-8696. 2005.
[7] M. Maas, P.J. Nelemans, V. Valentini, P. Das, C. Rodel, L.J. Kuo, F.A. Calvo, J. Garcia-Aguilar, R. Glynne-Jones, K. Haustermans, M. Mohiuddin, S. Pucciarelli, W. Small, Jr., J. Suarez, G. Theodoropoulos, S. Biondo, R.G. Beets-Tan, G.L. Beets. Long- term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. The Lancet. Oncology. 11: 835-844. 2010.
[8] L.F. de Campos-Lobato, L. Stocchi, A. da Luz Moreira, D. Geisler, D.W. Dietz, I.C. Lavery, V.W. Fazio, M.F. Kalady. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 18: 1590-1598. 2011.
[9] V. Valentini, C. Coco, A. Picciocchi, A.G. Morganti, L. Trodella, A. Ciabattoni, F. Cellini, B. Barbaro, S. Cogliandolo, G. Nuzzo, G.B. Doglietto, F. Ambesi-Impiombato, M. Cosimelli. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. International journal of radiation oncology, biology, physics. 53: 664- 674. 2002.
[10] B. Cedermark, M. Dahlberg, B. Glimelius, L. Pahlman, L.E. Rutqvist, N. Wilking. Improved survival with preoperative radiotherapy in resectable rectal cancer. The New England journal of medicine. 336: 980-987. 1997.
[11] J. Folkesson, H. Birgisson, L. Pahlman, B. Cedermark, B. Glimelius, U. Gunnarsson. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23: 5644-5650. 2005.
[12] E. Kapiteijn, C.A. Marijnen, I.D. Nagtegaal, H. Putter, W.H. Steup, T. Wiggers, H.J. Rutten, L. Pahlman, B. Glimelius, J.H. van Krieken, J.W. Leer, C.J. van de Velde. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. The New England journal of medicine. 345: 638-646. 2001.
[13] W. van Gijn, C.A. Marijnen, I.D. Nagtegaal, E.M. Kranenbarg, H. Putter, T. Wiggers, H.J. Rutten, L. Pahlman, B. Glimelius, C.J. van de Velde. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12- year follow-up of the multicentre, randomised controlled TME trial. The Lancet. Oncology. 12: 575-582. 2011.
[14] J.P. Gerard, T. Conroy, F. Bonnetain, O. Bouche, O. Chapet, M.T. Closon-Dejardin, M. Untereiner, B. Leduc, E. Francois, J. Maurel, J.F. Seitz, B. Buecher, R. Mackiewicz, M. Ducreux, L. Bedenne. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24: 4620-4625. 2006.
[15] J.F. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, E. Bardet, A. Beny, J.C. Ollier. Chemotherapy with preoperative radiotherapy in rectal cancer. The New England journal of medicine. 355: 1114-1123. 2006.
[16] A.B. Benson, 3rd, A.P. Venook, T. Bekaii-Saab, E. Chan, Y.J. Chen, H.S. Cooper, P.F. Engstrom, P.C. Enzinger, M.J. Fenton, C.S. Fuchs, J.L. Grem, A. Grothey, H.S. Hochster, S. Hunt, A. Kamel, N. Kirilcuk, L.A. Leong, E. Lin, W.A. Messersmith, M.F. Mulcahy, J.D. Murphy, S. Nurkin, E. Rohren, D.P. Ryan, L. Saltz, S. Sharma, D. Shibata, J.M. Skibber, C.T. Sofocleous, E.M. Stoffel, E. Stotsky-Himelfarb, C.G. Willett, K.M. Gregory, D. Freedman-Cass. Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 13: 719-728; quiz 728. 2015.
[17] S.Y. Ngan, B. Burmeister, R.J. Fisher, M. Solomon, D. Goldstein, D. Joseph, S.P. Ackland, D. Schache, B. McClure, S.A. McLachlan, J. McKendrick, T. Leong, C. Hartopeanu, J. Zalcberg, J. Mackay. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30: 3827-3833. 2012.
[18] C. Aschele, L. Cionini, S. Lonardi, C. Pinto, S. Cordio, G. Rosati, S. Artale, A. Tagliagambe, G. Ambrosini, P. Rosetti, A. Bonetti, M.E. Negru, M.C. Tronconi, G. Luppi, G. Silvano, D.C. Corsi, A.M. Bochicchio, G. Chiaulon, M. Gallo, L. Boni. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29: 2773-2780. 2011.
[19] J.P. Gerard, D. Azria, S. Gourgou-Bourgade, I. Martel-Lafay, C. Hennequin, P.L. Etienne, V. Vendrely, E. Francois, G. de La Roche, O. Bouche, X. Mirabel, B. Denis, L. Mineur, J.F. Berdah, M.A. Mahe, Y. Becouarn, O. Dupuis, G. Lledo, J.F. Seitz, L. Bedenne, B. Juzyna, T. Conroy. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30: 4558-4565. 2012.
[20] C. Rodel, U. Graeven, R. Fietkau, W. Hohenberger, T. Hothorn, D. Arnold, R.D. Hofheinz, M. Ghadimi, H.A. Wolff, M. Lang-Welzenbach, H.R. Raab, C. Wittekind, P. Strobel, L. Staib, M. Wilhelm, G.G. Grabenbauer, H. Hoffmanns, F. Lindemann, A. Schlenska-Lange, G. Folprecht, R. Sauer, T. Liersch. Oxaliplatin added to fluorouracil- based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 16: 979-989. 2015.
[21] T. Sato, H. Ozawa, K. Hatate, W. Onosato, M. Naito, T. Nakamura, A. Ihara, W. Koizumi, K. Hayakawa, I. Okayasu, K. Yamashita, M. Watanabe. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. International journal of radiation oncology, biology, physics. 79: 677-683. 2011.
[22] T. Sato, K. Hayakawa, N. Tomita, M. Noda, N. Kamikonya, T. Watanabe, D. Kato, Y. Sakai, M. Hiraoka, M. Shimada, H. Ikushima, H. Baba, N. Oya, M. Oya, K. Nemoto- Murofushi, M. Takeuchi, M. Watanabe. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 120: 222-227. 2016.
[23] K. Kawai, E. Sunami, K. Hata, T. Tanaka, T. Nishikawa, K. Otani, K. Sasaki, H. Nozawa. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer. Clinical colorectal cancer. 2018.
[24] A. Habr-Gama, R.O. Perez. Non-operative management of rectal cancer after neoadjuvant chemoradiation. The British journal of surgery. 96: 125-127. 2009.
[25] A. Habr-Gama, J. Gama-Rodrigues, G.P. Sao Juliao, I. Proscurshim, C. Sabbagh, P.B. Lynn, R.O. Perez. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. International journal of radiation oncology, biology, physics. 88: 822-828. 2014.
[26] M.J.M. van der Valk, D.E. Hilling, E. Bastiaannet, E. Meershoek-Klein Kranenbarg, G.L. Beets, N.L. Figueiredo, A. Habr-Gama, R.O. Perez, A.G. Renehan, C.J.H. van de Velde. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet (London, England). 391: 2537-2545. 2018.
[27] A.M. Maffione, F. Galeotti, C. Capirci, P.M. Colletti, D. Rubello. When and why to use FDG PET/CT in locally advanced rectal cancer: two scenarios. Clinical nuclear medicine. 39: 528-530. 2014.
[28] S.Y. Kim, J. Joo, T.W. Kim, Y.S. Hong, J.E. Kim, I.G. Hwang, B.G. Kim, K.W. Lee, J.W. Kim, H.S. Oh, J.B. Ahn, D.Y. Zang, D.Y. Kim, J.H. Oh, J.Y. Baek. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. International journal of radiation oncology, biology, physics. 101: 889-899. 2018.
[29] Y.S. Hong, B.H. Nam, K.P. Kim, J.E. Kim, S.J. Park, Y.S. Park, J.O. Park, S.Y. Kim, T.Y. Kim, J.H. Kim, J.B. Ahn, S.B. Lim, C.S. Yu, J.C. Kim, S.H. Yun, J.H. Kim, J.H. Park, H.C. Park, K.H. Jung, T.W. Kim. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. The Lancet. Oncology. 15: 1245-1253. 2014.
[30] P. Vaupel, O. Thews, M. Hoeckel. Treatment resistance of solid tumors: role of hypoxia and anemia. Medical oncology (Northwood, London, England). 18: 243-259. 2001.
[31] J.M. Brown, W.R. Wilson. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4: 437-447. 2004.
[32] N. Ferrara. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2: 795-803. 2002.
[33] M. Hockel, C. Knoop, K. Schlenger, B. Vorndran, E. Baussmann, M. Mitze, P.G. Knapstein, P. Vaupel. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 26: 45-50. 1993.
[34] Y. Dor, E. Keshet. Ischemia-driven angiogenesis. Trends in cardiovascular medicine. 7: 289-294. 1997.
[35] P.H. Maxwell, G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.L. Harris, I.J. Stratford, O. Hankinson, C.W. Pugh, P.J. Ratcliffe. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 94: 8104-8109. 1997.
[36] P. Carmeliet, Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C.J. Koch, P. Ratcliffe, L. Moons, R.K. Jain, D. Collen, E. Keshert. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394: 485-490. 1998.
[37] M. Koshiji, Y. Kageyama, E.A. Pete, I. Horikawa, J.C. Barrett, L.E. Huang. HIF- 1alpha induces cell cycle arrest by functionally counteracting Myc. Embo j. 23: 1949- 1956. 2004.
[38] S. Hammer, K.K. To, Y.G. Yoo, M. Koshiji, L.E. Huang. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle. 6: 1919-1926. 2007.
[39] N.C. Denko. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 8: 705-713. 2008.
[40] G. Bellot, R. Garcia-Medina, P. Gounon, J. Chiche, D. Roux, J. Pouyssegur, N.M. Mazure. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 29: 2570-2581. 2009.
[41] K. Hongo, N.H. Tsuno, K. Kawai, K. Sasaki, M. Kaneko, M. Hiyoshi, K. Murono, N. Tada, T. Nirei, E. Sunami, K. Takahashi, H. Nagawa, J. Kitayama, T. Watanabe. Hypoxia enhances colon cancer migration and invasion through promotion of epithelial- mesenchymal transition. The Journal of surgical research. 182: 75-84. 2013.
[42] D.M. Gilkes, G.L. Semenza, D. Wirtz. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 14: 430-439. 2014.
[43] J.T. Erler, C.J. Cawthorne, K.J. Williams, M. Koritzinsky, B.G. Wouters, C. Wilson, C. Miller, C. Demonacos, I.J. Stratford, C. Dive. Hypoxia-mediated down- regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 24: 2875-2889. 2004.
[44] H. Zhong, A.M. De Marzo, E. Laughner, M. Lim, D.A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza, J.W. Simons. Overexpression of hypoxia- inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59: 5830-5835. 1999.
[45] D. Cao, M. Hou, Y.S. Guan, M. Jiang, Y. Yang, H.F. Gou. Expression of HIF- 1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC cancer. 9: 432. 2009.
[46] G.L. Semenza. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3: 721-732. 2003.
[47] K. Murono, N.H. Tsuno, K. Kawai, K. Sasaki, K. Hongo, M. Kaneko, M. Hiyoshi, N. Tada, T. Nirei, E. Sunami, K. Takahashi, J. Kitayama. SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha. Anticancer Res. 32: 865-872. 2012.
[48] B.J. Moeller, Y. Cao, C.Y. Li, M.W. Dewhirst. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 5: 429-441. 2004.
[49] B.J. Moeller, M.R. Dreher, Z.N. Rabbani, T. Schroeder, Y. Cao, C.Y. Li, M.W. Dewhirst. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 8: 99-110. 2005.
[50] A. Miyasaka, K. Oda, Y. Ikeda, K. Sone, T. Fukuda, K. Inaba, C. Makii, A. Enomoto, N. Hosoya, M. Tanikawa, Y. Uehara, T. Arimoto, H. Kuramoto, O. Wada- Hiraike, K. Miyagawa, T. Yano, K. Kawana, Y. Osuga, T. Fujii. PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-alpha/VEGF pathway in endometrial cancer. Gynecologic oncology. 138: 174-180. 2015.
[51] H. Lu, K. Liang, Y. Lu, Z. Fan. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1alpha. Cancer Lett. 322: 78-85. 2012.
[52] D. Ahmed, P.W. Eide, I.A. Eilertsen, S.A. Danielsen, M. Eknaes, M. Hektoen, G.E. Lind, R.A. Lothe. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2: e71. 2013.
[53] S. Srinivasan, J.F. Dunn. Stabilization of hypoxia-inducible factor-1alpha in buffer containing cobalt chloride for Western blot analysis. Analytical biochemistry. 416: 120-122. 2011.
[54] K. Kawai, N.H. Tsuno, J. Kitayama, Y. Okaji, K. Yazawa, M. Asakage, N. Hori, T. Watanabe, K. Takahashi, H. Nagawa. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. The Journal of allergy and clinical immunology. 112: 951-957. 2003.
[55] K.G. Lai, Y.H. Lin, C.T. Ho, C.Y. Chen, C.Y. Peng, T.Z. Liu, J.F. Chiou. Paclitaxel pretreatment overcomes hypoxia inducible factor-1alpha-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells. Life sciences. 136: 7- 12. 2015.
[56] H. Harada, S. Kizaka-Kondoh, G. Li, S. Itasaka, K. Shibuya, M. Inoue, M. Hiraoka. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene. 26: 7508-7516. 2007.
[57] M.A. Pena-Rico, M.N. Calvo-Vidal, R. Villalonga-Planells, F. Martinez-Soler, P. Gimenez-Bonafe, A. Navarro-Sabate, A. Tortosa, R. Bartrons, A. Manzano. TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 101: 132-139. 2011.
[58] P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L.M. Greenberger, I.D. Horak. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clinical cancer research : an official journal of the American Association for Cancer Research. 14: 1888-1896. 2008.
[59] H. Kamiyama, S. Takano, K. Tsuboi, A. Matsumura. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol. 131: 205-213. 2005.
[60] K. Sasai, G.Z. Guo, K. Shibuya, N. Oya, T. Shibata, Y. Nagata, M. Hiraoka. Effects of SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation. International journal of radiation oncology, biology, physics. 42: 785-788. 1998.
[61] N. Kaneda, H. Nagata, T. Furuta, T. Yokokura. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715-1720. 1990.
[62] Y. Sasaki, Y. Yoshida, K. Sudoh, H. Hakusui, H. Fujii, T. Ohtsu, H. Wakita, T. Igarashi, K. Itoh. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Japanese journal of cancer research : Gann. 86: 111-116. 1995.
[63] N. Masuda, M. Fukuoka, S. Kudoh, K. Matsui, Y. Kusunoki, M. Takada, K. Nakagawa, T. Hirashima, H. Tsukada, T. Yana, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12: 1833-1841. 1994.
[64] N. Gombodorj, T. Yokobori, S. Yoshiyama, R. Kawabata-Iwakawa, S. Rokudai, I. Horikoshi, M. Nishiyama, T. Nakano. Inhibition of Ubiquitin-conjugating Enzyme E2 May Activate the Degradation of Hypoxia-inducible Factors and, thus, Overcome Cellular Resistance to Radiation in Colorectal Cancer. Anticancer Res. 37: 2425-2436. 2017.
[65] E.H. Kim, H. Lee, Y.K. Jeong, W.G. Jung. Mechanisms of SU5416, an inhibitor of vascular endothelial growth factor receptor, as a radiosensitizer for colon cancer cells. Oncol Rep. 36: 763-770. 2016.
[66] A. Saberi, D. Shahbazi-Gahrouei, M. Abbasian, M. Fesharaki, A. Baharlouei, Z. Arab-Bafrani. Gold nanoparticles in combination with megavoltage radiation energy increased radiosensitization and apoptosis in colon cancer HT-29 cells. International journal of radiation biology. 1-9. 2016.
[67] M. Vijay, G. Sivagami, K. Thayalan, N. Nalini. Radiosensitizing potential of rutin against human colon adenocarcinoma HT-29 cells. Bratislavske lekarske listy. 117: 171-178. 2016.
[68] X. Tian, M. Nguyen, H.P. Foote, J.M. Caster, K.C. Roche, C.G. Peters, P. Wu, L. Jayaraman, E.G. Garmey, J.E. Tepper, S. Eliasof, A.Z. Wang. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1alpha. Cancer Res. 77: 112-122. 2017.
[69] AJM Rombouts, N Hugen, MAG Elferink, ID Nagtegaal, JHW de Wilt. Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study. Ann Surg Oncol. 23: 3593-3601. 2016.
[70] B. Rau, M. Hunerbein, C. Barth, P. Wust, W. Haensch, H. Riess, R. Felix, P.M. Schlag. Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. Surgical endoscopy. 13: 980-984. 1999.
[71] D.A. Schneider, T.J. Akhurst, S.Y. Ngan, S.K. Warrier, M. Michael, A.C. Lynch, L. Te Marvelde, A.G. Heriot. Relative Value of Restaging MRI, CT, and FDG-PET Scan After Preoperative Chemoradiation for Rectal Cancer. Diseases of the colon and rectum. 59: 179-186. 2016.
[72] S.C. Nahas, C.S. Rizkallah Nahas, C.F. Sparapan Marques, U. Ribeiro, Jr., G.C. Cotti, A.R. Imperiale, F.C. Capareli, A.T. Chih Chen, P.M. Hoff, I. Cecconello. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer. Diseases of the colon and rectum. 59: 255-263. 2016.
[73] K. Kawai, S. Ishihara, H. Nozawa, K. Hata, T. Kiyomatsu, T. Morikawa, M. Fukayama, T. Watanabe. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer. Diseases of the colon and rectum. 60: 368-375. 2017.
[74] U.B. Patel, F. Taylor, L. Blomqvist, C. George, H. Evans, P. Tekkis, P. Quirke, D. Sebag-Montefiore, B. Moran, R. Heald, A. Guthrie, N. Bees, I. Swift, K. Pennert, G. Brown. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29: 3753- 3760. 2011.
[75] U.B. Patel, G. Brown, H. Rutten, N. West, D. Sebag-Montefiore, R. Glynne-Jones, E. Rullier, M. Peeters, E. Van Cutsem, S. Ricci, C. Van de Velde, P. Kjell, P. Quirke. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Annals of surgical oncology. 19: 2842-2852. 2012.
[76] S.K. Yu, D. Tait, I. Chau, G. Brown. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy? International journal of radiation oncology, biology, physics. 87: 505- 511. 2013.
[77] M. Chand, R.I. Swift, P.P. Tekkis, I. Chau, G. Brown. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. British journal of cancer. 110: 19-25. 2014.
[78] F. Sclafani, G. Brown, D. Cunningham, A. Wotherspoon, L.S.T. Mendes, S. Balyasnikova, J. Evans, C. Peckitt, R. Begum, D. Tait, J. Tabernero, B. Glimelius, S. Rosello, J. Thomas, J. Oates, I. Chau. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. British journal of cancer. 117: 1478-1485. 2017.
[79] C. Capirci, L. Rampin, P.A. Erba, F. Galeotti, G. Crepaldi, E. Banti, M. Gava, S. Fanti, G. Mariani, P.C. Muzzio, D. Rubello. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. European journal of nuclear medicine and molecular imaging. 34: 1583-1593. 2007.
[80] A.A. Martoni, F. Di Fabio, C. Pinto, P. Castellucci, S. Pini, C. Ceccarelli, D. Cuicchi, B. Iacopino, P. Di Tullio, S. Giaquinta, L. Tardio, R. Lombardi, S. Fanti, B. Cola. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22: 650-656. 2011.
[81] C. Zhang, J. Tong, X. Sun, J. Liu, Y. Wang, G. Huang. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. International journal of cancer. 131: 2604-2611. 2012.
[82] A.M. Maffione, M.C. Marzola, C. Capirci, P.M. Colletti, D. Rubello. Value of (18)F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. AJR. American journal of roentgenology. 204: 1261-1268. 2015.
[83] M.J. Murcia Durendez, L. Frutos Esteban, J. Lujan, M.D. Frutos, G. Valero, J.L. Navarro Fernandez, L. Mohamed Salem, G. Ruiz Merino, M.A. Claver Valderas. The value of 18F-FDG PET/CT for assessing the response to neoadjuvant therapy in locally advanced rectal cancer. European journal of nuclear medicine and molecular imaging. 40: 91-97. 2013.
[84] G.C. Park, J.S. Kim, J.L. Roh, S.H. Choi, S.Y. Nam, S.Y. Kim. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 24: 208-214. 2013.
[85] W. Huang, M. Fan, B. Liu, Z. Fu, T. Zhou, Z. Zhang, H. Gong, B. Li. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 55: 1584-1590. 2014.
[86] S.J. Kim, S. Chang. Volumetric parameters changes of sequential 18F-FDG PET/CT for early prediction of recurrence and death in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Clinical nuclear medicine. 40: 930-935. 2015.
[87] W. Sun, J. Xu, W. Hu, Z. Zhang, W. Shen. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 15: e231-238. 2013.
[88] S.K. Chennupati, A. Quon, A. Kamaya, R.K. Pai, T. La, T.E. Krakow, E. Graves, A.C. Koong, D.T. Chang. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. American journal of clinical oncology. 35: 334-339. 2012.
[89] S.J. Lee, J.G. Kim, S.W. Lee, Y.S. Chae, B.W. Kang, Y.J. Lee, J.S. Park, G.S. Choi. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer chemotherapy and pharmacology. 71: 1201-1207. 2013.
[90] J.I. Bang, S. Ha, S.B. Kang, K.W. Lee, H.S. Lee, J.S. Kim, H.K. Oh, H.Y. Lee, S.E. Kim. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer. European journal of nuclear medicine and molecular imaging. 43: 422-431. 2016.
[91] J.A. Ruby, T. Leibold, T.J. Akhurst, J. Shia, L.B. Saltz, M. Mazumdar, E.R. Riedel, S.M. Larson, J.G. Guillem. FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. Diseases of the colon and rectum. 55: 378-386. 2012.
[92] D.A. Dos Anjos, R.O. Perez, A. Habr-Gama, G.P. Sao Juliao, B.B. Vailati, L.M. Fernandez, J.B. de Sousa, C.A. Buchpiguel. Semiquantitative volumetry by sequential PET/CT may improve prediction of complete response to neoadjuvant chemoradiation in patients with distal rectal cancer. Dis Colon Rectum. 59: 805-812. 2016.
[93] J.D. Brierley, TNM classification of malignant tumours, 8th Edition, John Wiley & Sons2017.
[94] 大腸癌研究会編. 大腸癌取扱い規約 第 8 版 金原出版. 2013.
[95] T. Okuno, K. Kawai, K. Koyama, M. Takahashi, S. Ishihara, T. Momose, T. Morikawa, M. Fukayama, T. Watanabe. Value of FDG-PET/CT volumetry after chemoradiotherapy in rectal cancer. Dis Colon Rectum. 61: 320-327. 2018. https://journals.lww.com/dcrjournal/Fulltext/2018/03000/Value_of_FDG_PET_CT_Vol umetry_After.13.aspx
[96] U. Haberkorn, L.G. Strauss, C. Reisser, D. Haag, A. Dimitrakopoulou, S. Ziegler, F. Oberdorfer, V. Rudat, G. van Kaick. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 32: 1548-1555. 1991.
[97] H. Minn, A.C. Clavo, R. Grenman, R.L. Wahl. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 36: 252-258. 1995.
[98] R. Bos, J.J. van Der Hoeven, E. van Der Wall, P. van Der Groep, P.J. van Diest, E.F. Comans, U. Joshi, G.L. Semenza, O.S. Hoekstra, A.A. Lammertsma, C.F. Molthoff. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20: 379-387. 2002.
[99] C.C. Riedl, T. Akhurst, S. Larson, S.F. Stanziale, S. Tuorto, A. Bhargava, H. Hricak, D. Klimstra, Y. Fong. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 48: 771-775. 2007.
[100] M.K. Chung, H.S. Jeong, Y.I. Son, Y.K. So, G.Y. Park, J.Y. Choi, S.H. Hyun, H.J. Kim, Y.H. Ko, C.H. Baek. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Annals of surgical oncology. 16: 3111-3117. 2009.
[101] S.M. Larson, Y. Erdi, T. Akhurst, M. Mazumdar, H.A. Macapinlac, R.D. Finn, C. Casilla, M. Fazzari, N. Srivastava, H.W.D. Yeung, J.L. Humm, J. Guillem, R. Downey, M. Karpeh, A.E. Cohen, R. Ginsberg. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging: The Visual Response Score and the Change in Total Lesion Glycolysis. Clinical Positron Imaging. 2: 159-171. 1999.
[102] S. Pucciarelli, P. Toppan, M.L. Friso, V. Russo, L. Pasetto, E. Urso, F. Marino, A. Ambrosi, M. Lise. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Diseases of the colon and rectum. 47: 1798-1807. 2004.
[103] K. Kawai, H. Nozawa, K. Hata, T. Tanaka, T. Nishikawa, K. Oba, T. Watanabe. Optimal Interval for (18)F-FDG-PET After Chemoradiotherapy for Rectal Cancer. Clinical colorectal cancer. 17: e163-e170. 2018.
論文の公開元へ
